You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明合聯(02268.HK)香港發售股份獲49.96倍認購 上限定價每股20.6港元
格隆匯 11-16 07:02

格隆匯11月16日丨藥明合聯(02268.HK)發佈公吿,公司全球發售約1.78億股股份,中國香港發售股份5353.4萬股,國際發售股份約1.25億股;最終發售價已釐定為每股發售股份20.60港元,每手買賣單位500股;Morgan Stanley、Goldman Sachs及J.P. Morgan為聯席保薦人;預期股份將於2023年11月17日於聯交所主板掛牌上市。

中國香港發售股份已獲非常大幅超額認購。已接獲有效申請合計30,726份,合計認購約8.92億股,相當於發售股份總數約49.96倍。國際發售項下初步提呈發售的發售股份已獲大幅超額認購。合共約31.48億股國際發售股份已獲認購(包括基石投資者的認購),佔國際發售項下初步可供認購的股份總數(包括優先發售項下的892.2萬股預留股份)約19.60倍。根據發售價每股發售股份20.60港元,基石投資者將獲分配合共約1.14億股發售股份。

按發售價每股發售股份20.60港元計算,公司將自全球發售收取的所得款項淨額估計約為34.83億港元。公司擬將全球發售所得款項淨額約67.0%用於在新加坡興建生產設施及擴大在中國的抗體中間體產能,以進一步擴大生產能力;所得款項淨額約23.0%將用於有選擇地尋求戰略聯盟、投資及收購機會,以主要擴大技術平台及服務類型以及能力;及所得款項淨額的約10.0%用作營運資金及其他一般公司用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account